Our data elucidates a function of PRKAR2A deficiency in ameliorating DSS-induced colitis, which was earlier unidentified, thus suggesting that PRKAR2A might contribute to the unsatisfactory results of PDE4 inhibitor in the IBD clinical trial. This evidence concerns the gene PRKAR2A and colitis.